You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novo Nordisk A/S (NVO) - free report >>
Alaska Air Group, Inc. (ALK) - free report >>
Theravance Biopharma, Inc. (TBPH) - free report >>
Image: Shutterstock
New Strong Buy Stocks for February 14th
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
Inspire Medical Systems, Inc. (INSP - Free Report) : This medical technology company has seen the Zacks Consensus Estimate for its current year earnings increasing 40.6% over the last 60 days.
Inspire Medical Systems, Inc. Price and Consensus
Inspire Medical Systems, Inc. price-consensus-chart | Inspire Medical Systems, Inc. Quote
Alaska Air Group, Inc. (ALK - Free Report) : This airline company has seen the Zacks Consensus Estimate for its current year earnings increasing 7.7% over the last 60 days.
Alaska Air Group, Inc. Price and Consensus
Alaska Air Group, Inc. price-consensus-chart | Alaska Air Group, Inc. Quote
STRATA Skin Sciences, Inc. (SSKN - Free Report) : This dermatology-focused medical technology company has seen the Zacks Consensus Estimate for its current year earnings increasing 5% over the last 60 days.
Strata Skin Sciences, Inc. Price and Consensus
Strata Skin Sciences, Inc. price-consensus-chart | Strata Skin Sciences, Inc. Quote
Novo Nordisk A/S (NVO - Free Report) : This pharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 4.2% over the last 60 days.
Novo Nordisk A/S Price and Consensus
Novo Nordisk A/S price-consensus-chart | Novo Nordisk A/S Quote
Theravance Biopharma, Inc. (TBPH - Free Report) : This biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 2.3% over the last 60 days.
Theravance Biopharma, Inc. Price and Consensus
Theravance Biopharma, Inc. price-consensus-chart | Theravance Biopharma, Inc. Quote
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.